GLP-1 / Ozempic litigation
Ozempic, Wegovy, Mounjaro, Rybelsus (semaglutide, tirzepatide)
- Alleged injuries
- Gastroparesis, intestinal blockage (ileus), vision loss (NAION)
- What plaintiffs allege
- Plaintiffs allege GLP-1 makers failed to warn that the drugs can cause severe, sometimes permanent gastrointestinal injury and sudden vision loss.
- Scale
- 3,100+ federal cases — one of the fastest-growing dockets (up 130% in a year)
- Latest
- Case filings accelerated through 2025–2026 as vision-loss claims joined the gastroparesis docket.
What we’d look for in your records
